Cyclopharm (ASX:CYC) launched a 12-month clinical trial with Western University in Canada to investigate whether its Technegas technology can reveal hidden lung airflow issues in young adults with mild asthma, according to a Friday filing with the Australian bourse.
The clinical trial will enroll 40 participants aged 17 to 35 with mild asthma to investigate hidden lung airflow issues that may not be detectable through symptoms alone, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.